临床试验/NCT04546009

NCT04546009

进行中（未招募）

3 期

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Hoffmann-La Roche377 个研究点分布在 6 个国家目标入组 992 人2020年10月9日

适应症Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

干预措施Letrozole Giredestrant Letrozole-matched Placebo Palbociclib LHRH Agonist Giredestrant-matched Placebo

概览

阶段: 3 期
干预措施: Letrozole
疾病 / 适应症: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
发起方: Hoffmann-La Roche
入组人数: 992
试验地点: 377
主要终点: Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1
状态: 进行中（未招募）
最后更新: 2个月前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

注册库

clinicaltrials.gov

开始日期

2020年10月9日

结束日期

2028年3月25日

最后更新

2个月前

研究类型

Interventional

研究设计

Parallel

性别

All

研究者

发起方

Hoffmann-La Roche

责任方

Sponsor

入排标准

入选标准

•For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for the duration of study treatment
•Locally advanced (recurrent or progressed) or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
•Documented ER-positive tumor and HER2-negative tumor, assessed locally
•Patients who have bilateral breast cancers which are both ER-positive and HER2-negative can be included in the study because the metastases are suitably targeted by the study treatments. If patients have bilateral tumors which are of different biomarker status, then proof of the ER and HER2 status of the metastases is required for study entry
•No history of systemic anti-cancer therapy for locally advanced (recurrent or progressed) or metastatic disease
•Disease recurrence from early-stage breast cancer after standard adjuvant endocrine therapy meeting the protocol-defined criteria of having received at least 24 months of treatment without disease progression during treatment and a disease-free interval since the completion of treatment that was greater than 12 months
•Measurable disease as defined per RECIST v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
•Eastern Cooperative Oncology Group Performance Status 0-1
•Adequate organ function

排除标准

•Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with any CDK4/6 inhibitor
•Prior treatment with a selective estrogen receptor degrader (SERD)
•Treatment with any investigational therapy within 28 days prior to study treatment
•Treatment with strong CYP3A inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
•Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
•Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease
•Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
•Pregnant or breastfeeding

研究组 & 干预措施

Letrozole + Giredestrant-matched Placebo + Palbociclib

干预措施: Letrozole

Giredestrant + Letrozole-matched Placebo + Palbociclib

干预措施: Giredestrant

Giredestrant + Letrozole-matched Placebo + Palbociclib

干预措施: Letrozole-matched Placebo

Giredestrant + Letrozole-matched Placebo + Palbociclib

干预措施: Palbociclib

Giredestrant + Letrozole-matched Placebo + Palbociclib

干预措施: LHRH Agonist

Letrozole + Giredestrant-matched Placebo + Palbociclib

干预措施: Giredestrant-matched Placebo

Letrozole + Giredestrant-matched Placebo + Palbociclib

干预措施: Palbociclib

Letrozole + Giredestrant-matched Placebo + Palbociclib

干预措施: LHRH Agonist

结局指标

主要结局

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1

时间窗: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)

次要结局

Overall Survival(From randomization to death from any cause (up to 78 months))
Objective Response Rate, as Determined by the Investigator According to RECIST v1.1(From randomization until disease progression or death (up to 78 months))
Duration of Response, as Determined by the Investigator According to RECIST v1.1(From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to 78 months))
Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1(From randomization until disease progression or death (up to 78 months))
Time to Confirmed Deterioration in Pain Level, Defined as the Time to First Documented ≥2-Point Increase from Baseline in the 'Worst Pain' Item from the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire(From Baseline until treatment discontinuation (up to 78 months))
Time to Confirmed Deterioration in Pain Presence and Interference, Defined as the Time to First Documented ≥10-Point Increase from Baseline in the EORTC QLQ-C30 Linearly Transformed Pain Scale Score(From Baseline until treatment discontinuation (up to 78 months))
Time to Confirmed Deterioration in Physical Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Physical Functioning Scale Score(From Baseline until treatment discontinuation (up to 78 months))
Time to Confirmed Deterioration in Role Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Role Functioning Scale Score(From Baseline until treatment discontinuation (up to 78 months))
Time to Confirmed Deterioration in Global Health Status and Quality of Life (GHS/QoL), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed GHS/QoL Scale Score(From Baseline until treatment discontinuation (up to 78 months))
Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)(From treatment initiation until 30 days after the final dose of study treatment (up to 78 months))
Number of Participants with Vital Sign Abnormalities Over the Course of the Study(Baseline, Days 1 and 15 of Cycles 1 and 2, and Day 1 of each cycle thereafter until treatment discontinuation (1 cycle is 28 days))
Plasma Concentration of Giredestrant at Specified Timepoints(Days 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 8, and 16 (1 cycle is 28 days))
Plasma Concentration of Palbociclib at Specified Timepoints(Days 1 and 15 of Cycle 1 (1 cycle is 28 days))